MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.

Heightened aerobic glycolysis and glutaminolysis are characteristic metabolic phenotypes in cancer cells. Neuroblastoma (NBL), a devastating pediatric cancer, is featured by frequent genomic amplification of MYCN, a member of the Myc oncogene family that is primarily expressed in the early stage of embryonic development and required for neural crest development. Here we report that an enriched glutaminolysis gene signature is associated with MYCN amplification in children with NBL. The partial knockdown of MYCN suppresses glutaminolysis in NBL cells. Conversely, forced overexpression of MYCN in neural crest progenitor cells enhances glutaminolysis. Importantly, glutaminolysis induces oxidative stress by producing reactive oxygen species rendering NBL cells sensitive to augmentation. Through a small-scale metabolic-modulator screening, we have found that dimethyl fumarate (DMF), a Food and Drug Administration-approved drug for multiple sclerosis, suppresses NBL cell proliferation in vitro and tumor growth in vivo. DMF suppresses NBL cell proliferation through inducing duanyu1670 and subsequently suppressing MYCN expression, which is rescued by an duanyu1670 scavenger. Our findings suggest that the metabolic modulation and duanyu1670 augmentation could be used as novel strategies in treating NBL and other MYC-driven cancers.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}